BIOTECHNOLOGY-BASED APPROACHES FOR THE DEVELOPMENT OF NEXT-GENERATION THERAPEUTIC MOLECULES
Keywords:
Biotechnology; therapeutic proteins; monoclonal antibodies; mRNA therapeutics; CRISPR; cell therapy; antibody-drug conjugates; biomanufacturingAbstract
Biotechnology has expanded the therapeutic design space beyond conventional small molecules by enabling the rational construction, expression and delivery of proteins, antibodies, nucleic acids and engineered cellular systems. This structured narrative review evaluates major biotechnology-based approaches that are shaping next-generation therapeutics, with emphasis on recombinant and engineered proteins, monoclonal and multispecific antibodies, antibody-drug conjugates, messenger RNA and RNA interference platforms, genome editing, engineered cells, and advanced biomanufacturing. Peer-reviewed international literature was prioritized to identify enabling technologies, translational advantages, manufacturing requirements and safety constraints. Across therapeutic classes, the strongest trend is convergence: molecular engineering is increasingly combined with precision delivery, advanced analytics, synthetic biology and quality-by-design principles. Engineered proteins benefit from structural and chemical optimization, while antibody formats provide modular targeting and effector control. RNA medicines offer programmable and comparatively rapid redesign, but delivery, innate immune activation and tissue selectivity remain central challenges. CRISPR-based technologies enable durable genetic correction, although off-target activity, delivery and long-term safety require rigorous control. Cell therapies add adaptive biological functions but introduce complex manufacturing, phenotypic variability and logistics. Continuous processing, cell-free systems and molecular farming may improve production flexibility and access. The evidence indicates that future therapeutic innovation will depend less on a single platform than on integrated biotechnology systems that connect design, manufacturability, delivery, safety and clinical translation from the earliest development stages.
References
1. Ebrahimi, S. B., & Samanta, D. (2023). Engineering protein-based therapeutics through structural and chemical design. Nature Communications, 14, 2411.
2. Carter, P. J., & Quarmby, V. (2024). Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics. Nature Reviews Drug Discovery, 23, 898-913.
3. Klein, C., Brinkmann, U., Reichert, J. M., et al. (2024). The present and future of bispecific antibodies for cancer therapy. Nature Reviews Drug Discovery, 23, 301-319.
4. Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M., & Beck, A. (2023). Antibody-drug conjugates come of age in oncology. Nature Reviews Drug Discovery, 22, 641-661.
5. Tsuchikama, K., Anami, Y., Ha, S. Y. Y., & Yamazaki, C. M. (2024). Exploring the next generation of antibody-drug conjugates. Nature Reviews Clinical Oncology, 21, 203-223.
6. Metkar, M., Pepin, C. S., & Moore, M. J. (2024). Tailor made: The art of therapeutic mRNA design. Nature Reviews Drug Discovery, 23, 67-83.
7. Tang, Q., & Khvorova, A. (2024). RNAi-based drug design: Considerations and future directions. Nature Reviews Drug Discovery, 23, 341-364.
8. Barber, H. M., Pater, A. A., Gagnon, K. T., Damha, M. J., O'Reilly, D., et al. (2025). Chemical engineering of CRISPR-Cas systems for therapeutic application. Nature Reviews Drug Discovery, 24, 209-230.
9. Madigan, V., Zhang, F., & Dahlman, J. E. (2023). Drug delivery systems for CRISPR-based genome editors. Nature Reviews Drug Discovery, 22, 875-894.
10. Androsavich, J. R. (2024). Frameworks for transformational breakthroughs in RNA-based medicines. Nature Reviews Drug Discovery, 23, 421-444.
11. Li, Z., Wang, Y., Gu, Z., & Hu, Q. (2024). Engineering cells for therapy and diagnosis. Nature Reviews Bioengineering, 2, 770-784.
12. Wang, L. L. W., Gao, Y., Feng, Z., Mooney, D. J., & Mitragotri, S. (2024). Designing drug delivery systems for cell therapy. Nature Reviews Bioengineering, 2, 944-959.
13. Eidenberger, L., Kogelmann, B., & Steinkellner, H. (2023). Plant-based biopharmaceutical engineering. Nature Reviews Bioengineering, 1, 426-439.
